The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities.
The company has development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection.
- Sector: Healthcare
- Industry: Biotechnology
- Full Time Employees: 146
- Founded in 2006
- Headquartered in Durham, North Carolina
- http://www.precisionbiosciences.com
Precision BioSciences (DTIL) priced 7.9 mln share IPO at $16.00 per share, the midpoint of the expected $15-17 per share range
Opened for trading at $18.00
No comments:
Post a Comment